Abstract
multiple known pre-operative predictors for APFs were significant on MVA, and multiple predictors were associated with PFS on UVA. Therefore, PCA3 may not be a useful adjunct predictive marker in men with intermediate-or high-risk PCa.
Introduction
Prostate cancer gene 3 (PCA3) is highly overexpressed by prostate cancer (PCa) cells and is a validated biomarker that predicts for the presence of PCa when prostate-specific antigen (PSA) levels are in an indeterminate range.
1-3 PCA3 scores, which are determined by calculating the ratio of PCA3 mRNA to PSA mRNA in the urine, also have particular utility for guiding repeat biopsy decisions in men with previous negative biopsies. 2 Furthermore, and of importance in upfront treatment discussions, PCA3 scores have been demonstrated to be predictive for highgrade PCa, significantly improving clinical models for diagnosing prostate cancer. 4 In men with predominantly favorable-risk PCa (i.e. predominantly low-or intermediaterisk PCa per the National Comprehensive Cancer Network stratification schema), PCA3 testing has also been investigated for its potential utility in predicting adverse pathologic features at radical prostatectomy (RP), with mixed results. Several studies found significant correlations with increasing PCA3 score and increased rates of higher risk disease, extracapsular extension, pathologic Gleason score (GS), tumor volume, tumor multifocality, and positive surgical margins (PSM). [5] [6] [7] [8] [9] [10] [11] However, other studies found minimal, if any, association between PCA3 scores and adverse pathologic features and/or noted that PCA3 scores offered no incremental value to existing models for predicting adverse pathology. [12] [13] [14] [15] However, the potential associations of PCA3 score with adverse pathologic features have not been evaluated in a predominantly higher-risk PCa population (i.e., a population with more intermediate-and high-risk PCa patients). Additionally, whether PCA3 scores can have prognostic utility with regards to progression-free survival (PFS) remains unknown. Therefore, we retrospectively evaluated the association between PCA3 scores and both adverse pathologic features and PFS in a cohort of men with higher-risk PCa who underwent RP at a single institution.
Material & Methods

Patient Selection
The study cohort consisted of 109 men with clinically localized (cT1-T2), intermediateor high-risk PCa who had PCA3 urine assay testing prior to treatment with RP between 2010 and 2015 at a single academic medical center. The criteria used for ordering PCA3 testing included evaluation for the probability of undiagnosed PCa in men with an elevated PSA (>4 ng/mL) or for aiding in the management of men with one or multiple negative prostate biopsy procedures but a persistently elevated or rising PSA. This study was approved as part of an Institutional
Review Board (IRB)-approved protocol evaluating a registry of men with higher-risk PCa.
Urinary PCA3 Assay
Following digital prostatic massage, first-catch urine was collected from all patients as described in Groskopf et al. 16 The urine sample was analyzed to quantify PCA3-mRNA and PSA-mRNA concentrations. The PCA3 score was calculated by taking the ratio of PCA3 mRNA to PSA mRNA and multiplying this by 1000.
Pathologic Specimens
The pathologic specimens of the 109 men who underwent RP were step-sectioned and reviewed by an expert, academic genitourinary pathologist. Evidence of extracapsular extension 
Progression-Free Survival
Disease progression was defined as biochemical recurrence, treatment with postoperative radiotherapy or androgen deprivation therapy (ADT), or the development of distant metastasis from PCa. No patients died during the period of this study. Biochemical recurrence was defined according to the American Urological Association guidelines (i.e. an initial serum PSA > 0.2 ng/mL with a subsequent confirmatory PSA 19 ), or the initiation of salvage radiotherapy.
Statistical Methods
The distributions of clinical, biopsy, imaging, and pathologic characteristics of the entire study cohort (n=109) and the subset with > 1 year of follow-up (n=78) were calculated. 
Results
The Distribution of Characteristics of the Study Cohort
The distributions of clinical, biopsy, imaging, and pathologic characteristics of the entire cohort and the subset with > 1 year of follow-up evaluated for PFS are reported in Table 1 . The median age of the entire cohort was 65 years (interquartile range (IQR) 59-69). The median PCA3 score was 47 (IQR 23-73). Median PSA was 7.4 (IQR 5.3-11.7). All patients had clinically localized prostate cancer (86% T1c and 14% T2). Forty percent had bGS < 3+4, 14%
had bGS 4+3, and 47% had bGS 8-10. Forty-eight percent had intermediate-risk and 52% had high-risk prostate cancer. Nine percent of patients had evidence of T3 disease on MRI.
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At RP, 52% of patients had at least one adverse pathologic feature. Overall, 32% had pT3a disease, 10% had pT3b disease, and 10% had pN+ disease. Twenty-one percent experienced GS upgrading and 41% were upstaged to pT3. The subset of patients with > 1 year follow-up had similar distributions for all clinical, biopsy, imaging, and pathologic characteristics.
Univariate and Multivariate Logistic Regression Analysis: Adverse Pathologic Features
Univariate and multivariate analyses for the presence of ECE without SVI, SVI, and upstaging to pathological ≥T3a are presented in (Table 2 ). Logistic regression analyses evaluating upgrading at RP to pGS 8-10 or to tertiary Gleason pattern 5 are reported in Table 3 .
bGS was the only variable associated with upgrading on univariate analysis (p=0.030).
Similar regression analyses were also performed for predictors of PSMs (Table S1 ), any adverse pathologic feature (as a composite outcome) other than PSM (Table S2) , and any adverse pathologic feature (as a composite outcome) including PSM ( Therefore, the absence of an association in our study is unlikely to be related to an issue of statistical power and suggests limited, if any, utility of PCA3 as an adjunct predictive marker for adverse pathology. On the other hand, the lack of an association between PCA3 score and PFS may be ascribed to the short median follow-up of 2.3 years and 3-year progression rate of 30%.
However, other canonical factors were at least predictive of PFS on univariate analyses, suggesting that an association between PCA3 and PFS, if present, is modest in strength at best.
Still, the uncertain clinical significance of biochemical recurrence 26 -the most common form of progression seen in this cohort-renders conclusions about PCA3 scoring and ultimate clinical outcome premature.
Interestingly, a recently published study evaluating the Decipher Genomic Resource
Information (GRID™) PCa database found that low PCA3 expression was associated with higher-grade disease and disease progression. 27 While this study is different from ours since it evaluated PCA3 gene expression profiles in prostatic tissues rather than PCA3 score with the urine assay, the findings further suggest that the convention of using PCA3 to determine the risk of finding PCa at biopsy may be beneficial only in men with (as yet undiscovered) lower-risk disease. These results contrast with an earlier evaluation of the addition of urinary PCA3 score to a clinical risk nomogram, which noted that a higher PCA3 score was associated with highergrade disease at biopsy and that a nomogram including PCA3 scores outperformed one without them for the identification of PCa. 4 However, other large series have suggested selecting the appropriate PCA3 score threshold is integral to avoid under-diagnosis of high-grade disease.
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These limitations have led to proposals of combining PCA3 data with other biomarkers, including TMPRSS2:ERG fusion status. 29, 30 Perhaps including these novel biomarker assays individually or in combination in the pre-operative setting may improve the ability of existing pre-operative risk models to predict adverse pathologic features at RP and disease progression.
This study has several limitations, including all limitations inherent to a retrospective study. This study only included patients who were definitively treated with RP, and thus the results are not generalizable to patients receiving other forms of definitive treatment.
Furthermore, this study evaluated a small cohort of patients. Regardless, adverse pathologic features were common, and multiple known pre-operative predictors of adverse pathologic features were significant on multivariate analyses. However, the small cohort size along with the short median follow-up translated to a disease progression rate of only 30% at 3-years. Even expected predictors of PFS failed to manifest on multivariate analyses (though they did manifest on univariate analyses), raising the possibility that our results might change with added patients and/or added follow-up. In addition, the PCA3 values in the study cohort are somewhat low (median 47, IQR 23-73). As some studies establishing associations between PCA3 and adverse features were performed in cohorts with higher median PCA3 values, 8, 11, 12, 14 a study evaluating higher-risk men with higher PCA3 scores may yield different findings. Indeed, the study population may have PCA3 values below the threshold needed to predict adverse outcomes.
Conclusions
In conclusion, PCA3 score was not associated with any adverse pathologic features or with PFS in a cohort of patients with intermediate-and high-risk PCa, though canonical predictors were associated with adverse pathologic features on univariate and multivariate analyses, and with PFS on univariate analyses. Together, these results suggest that urine PCA3
testing may not be a useful adjunct predictor of outcomes in men with higher-risk PCa and underscore the need for improved risk assessment and prognostication tools for these patients. 
